NEW INTRODUCING OUR IMPROVE QUALITY OF LIFE IVABRADINE Versus placebo, Ivabradine has shown1 : 18% reduction in primary endpoint, driven by • a reduction in hospitalisation for HF • a reduction in death due to HF For further product information contact PHARMA DYNAMICS Email info@pharmadynamics.co.za CUSTOMER CARE LINE +27 21 707 7000 www.mydynamics.co.za IVOLAN 5 mg. Each tablet contains Ivabradine oxalate equivalent to 5 mg Ivabradine base. S3 51/7.1.4/0921. For full prescribing information, refer to the professional information approved by SAHPRA, March 2021. 1) K Swedberg et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85. IVNA842/05/2022
RkJQdWJsaXNoZXIy NDIzNzc=